WikiTrademarks - Search, analyse, and monitor trademark applications.

Trademark: TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES

Put your brand on the blockchain and timestamp its proof of existence at wikitrademarks.io

Tweet this

Track updates on TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES

Mark Identification

Proof of use for TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES

We do not have any records of a proof of use for TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES at this moment.

Click here to add a proof of use for TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES

Possible trademark infringements of TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES

Basic Information about TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES

Serial Number
97769288
Filing Date
26 Jan 2023
Mark Drawing Code
4

Classifications

Declare the trademark use of TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES on the blockchain with WikiTrademarks.io.

First use of TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES anywhere
No first use declared yet.
First use in commerce
There is no first use of this trademark in commerce detected yet.
Status Code
6
International Code
005
US Codes
005; 006; 018; 044; 046; 051; 052
First use of TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES anywhere
No first use declared yet.
First use in commerce
There is no first use of this trademark in commerce detected yet.
Status Code
6
International Code
042
US Codes
100; 101

Who owns TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES?

1. Replimune Limited Abingdon, Oxfordshire

Correspondent

MELANIE HOWARD
LOEB & LOEB LLP
10100 SANTA MONICA BOULEVARD, SUITE 2200
LOS ANGELES, CA 90067

Put your brand on the blockchain and timestamp its proof of existence at Wikitrademarks.io

Tweet this

Track updates on TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES